Filtered By:
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 1110 results found since Jan 2013.
Understanding Caregiver Goals, Benefits, and Acceptable Risks of Peanut Allergy Therapies
Peanut allergy affects 1.4-4.5% of children and may be a lifelong allergy in 75%.1 Nearly 50% of peanut allergic individuals have had a past severe reaction.2 Several promising peanut allergy treatments are under development.3 Peanut allergy is associated with anxiety and poor quality of life (QoL) in the child and caregiver, driven by fear the child will react from an accidental exposure —something treatment could prevent.4–10 For these reasons, two therapies, peanut oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT), have been granted US Food and Drug Administration (FDA) fast-track status.
Source: Annals of Allergy, Asthma and Immunology - June 22, 2018 Category: Allergy & Immunology Authors: Matthew Greenhawt, Rebekah Marsh, Hannah Gilbert, Scott Sicherer, Audrey DunnGalvin, Dan Matlock Source Type: research
The Current State of Epicutaneous Immunotherapy for Food Allergy: a Comprehensive Review
AbstractThe food allergy epidemic of recent years has led to the search for safe and effective methods of immunotherapy for foods. Studies of epicutaneous immunotherapy (EPIT) in mice have shown promising safety and efficacy data. Murine models have also identified probable mechanisms for the development of tolerance to food allergens, including the induction of regulatory T cells. Clinical data is lacking, but relatively small and early studies among peanut and cow ’s milk allergic subjects suggest that EPIT has an excellent safety profile, particularly compared to other methods of specific allergen immunotherapy. Effic...
Source: Clinical Reviews in Allergy and Immunology - October 28, 2017 Category: Allergy & Immunology Source Type: research
Emerging developments in the forefront of peanut oral immunotherapy
Purpose of review
Despite the COVID-19 pandemic, progress continued in the field of peanut oral immunotherapy over the past 12 to 18 months. Of importance, the first oral immunotherapy product for the treatment of peanut allergy was approved by the US Food and Drug Administration in January 2020.
Recent findings
Suggested modifications to the practice of oral immunotherapy, some of which may have lasting impacts, were circulated as a result of the pandemic. New advances in pathophysiology, sustained unresponsiveness, quality of life, safety, and cost effectiveness were also published.
Summary
During 202...
Source: Current Opinion in Allergy and Clinical Immunology - April 30, 2021 Category: Allergy & Immunology Tags: FOOD ALLERGY: Edited by Alessandro Fiocchi and Motohiro Ebisawa Source Type: research
Chapter 17: Immunomodulation of allergic sinonasal disease.
Abstract
IgE hypersensitivity is important to the pathogenesis of allergic diseases and the development and persistence of airway inflammation. Allergic immunomodulation encompasses various therapies that attempt to suppress or modify the immune mechanisms responsible for IgE-mediated disease. These include allergy immunotherapy (AIT) in the forms of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT), as well as the emergence of biological agents, such as anti-IgE, for allergic respiratory disease. Clinical evidence strongly supports the efficacy and safety of AIT for the treatment of allergic r...
Source: American Journal of Rhinology and Allergy - May 1, 2013 Category: ENT & OMF Authors: Settipane RA, Peters AT, Borish L Tags: Am J Rhinol Allergy Source Type: research
Sanofi Allergy Drug Safe for Non-prescription Use: FDA ReviewersSanofi Allergy Drug Safe for Non-prescription Use: FDA Reviewers
Sanofi SA's allergy drug Nasacort AQ is safe enough to be used without a prescription, according to reviewers for the U.S. Food and Drug Administration. Reuters Health Information
Source: Medscape Today Headlines - July 30, 2013 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
Isotretinoin treatment in a patient with known peanut allergy and positive IgE test results for soybean
Isotretinoin is a retinoid that is approved by the US Food and Drug Administration for the treatment of acne vulgaris and used off label for other dermatologic conditions, including hidradenitis suppurativa (HS). Isotretinoin decreases comedones and sebum production, influences cell-cycle progression, and reduces inflammation.1 Prescribing information leaflets state that oral isotretinoin is contraindicated in patients with known allergy to isotretinoin, peanut, or soya.2 Soybean oil is found within the capsules; thus, patients with peanut allergy might be considered at risk because of the known cross-reactivity between soybean and peanut.
Source: Annals of Allergy, Asthma and Immunology - September 22, 2016 Category: Allergy & Immunology Authors: Santiago Alvarez-Arango, Angela Hou, Michelle A. Lowes, Elina Jerschow Tags: Letter Source Type: research
Consensus Report from the Food Allergy Research and Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit
Food allergy is a major health problem affecting 5 to 10% of the population in developed nations, including an estimated 32 million Americans. Despite the large number of patients suffering from food allergies, up until the end of January 2020, no treatment for food allergies had been approved by the U.S. Food and Drug Administration (FDA). The only options were avoidance of food allergen triggers and acute management of allergic reactions. A considerable body of data exists supporting oral immunotherapy (OIT) as a promising, novel treatment option, including that for the now FDA-approved peanut OIT product, Palforzia.
Source: Journal of Allergy and Clinical Immunology - June 2, 2020 Category: Allergy & Immunology Authors: Amber N. Pepper, Amal Assa'ad, Michael Blaiss, Emily Brown, Sharon Chinthrajah, Christina Ciaccio, Mary Beth Fasano, Ruchi Gupta, Nurry Hong, David Lang, Todd Mahr, Erin Malawer, Anita Roach, Wayne Shreffler, Scott Sicherer, Kathleen Vickers, Brian P. Vic Source Type: research
Consensus report from the Food Allergy Research & Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit
Food allergy is a major health problem affecting 5% to 10% of the population in developed nations, including an estimated 32 million Americans. Despite the large number of patients suffering from food allergies, up until the end of January 2020, no treatment for food allergies had been approved by the US Food and Drug Administration. The only options were avoidance of food allergen triggers and acute management of allergic reactions. A considerable body of data exists supporting oral immunotherapy (OIT) as a promising, novel treatment option, including that for the now Food and Drug Administration–approved peanut OIT p...
Source: Journal of Allergy and Clinical Immunology - June 2, 2020 Category: Allergy & Immunology Authors: Amber N. Pepper, Amal Assa ’ad, Michael Blaiss, Emily Brown, Sharon Chinthrajah, Christina Ciaccio, Mary Beth Fasano, Ruchi Gupta, Nurry Hong, David Lang, Todd Mahr, Erin Malawer, Anita Roach, Wayne Shreffler, Scott Sicherer, Kathleen Vickers, Brian P. Source Type: research
Oral Immunotherapy for Food Allergy —a US Regulatory Perspective
AbstractThe recent approval of Palforzia for treatment of peanut allergy by the US Food and Drug Administration (USFDA) predicts that additional products for oral immunotherapy (OIT) are on the horizon. In this article, the authors review the legal framework by which the USFDA regulates products for OIT of food allergy and the clinical data that demonstrated that the safety and effectiveness profile of Palforzia supported approval and conclude with a discussion of oral food challenge (OFC) as a clinical endpoint to demonstrate safety and effectiveness of OIT products.
Source: Current Allergy and Asthma Reports - October 15, 2020 Category: Allergy & Immunology Source Type: research
Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy?
Allergen-specific subcutaneous immunotherapy confers significant clinical benefits in patients with grass pollen–induced allergic rhinoconjunctivitis. Nevertheless, treatment is costly; it lasts up to 5 years and can occasionally lead to systemic adverse reactions. Improving immunotherapy by means of direct administration of the allergen extract into a lymph node with 3 intralymphatic injections has been attempted in 3 previous studies. Two of the studies have shown efficacy in nasal provocations for grass pollen and cat dander. One small study combining patients with grass and birch pollen allergy has demonstrated an im...
Source: Journal of Allergy and Clinical Immunology - September 16, 2013 Category: Allergy & Immunology Authors: Marianne Witten, Hans-Jørgen Malling, Lars Blom, Britta C. Poulsen, Lars K. Poulsen Tags: Letters to the Editor Source Type: research
Quality of life improves significantly after real-world oral immunotherapy for children with peanut allergy
Peanut oral immunotherapy (POIT) is a novel and active form of treatment for patients with peanut allergy, with multiple research studies supporting its efficacy and safety. However, there are limited data available on changes in patients' quality of life (QoL) after successful desensitization. The Food and Drug Administration in the United States recently approved the first POIT drug for commercial use.
Source: Annals of Allergy, Asthma and Immunology - April 7, 2020 Category: Allergy & Immunology Authors: Andrea C. Blackman, Kristen A. Staggers, Lauren Kronisch, Carla M. Davis, Aikaterini Anagnostou Source Type: research
Clinical Use Of Biologics For Asthma Treatment By Allergy Specialists: A Questionnaire Survey
Asthma is a heterogeneous disease with emerging phenotypes and endotypes. Currently, five distinct biologics are Food and Drug Administration (FDA)-approved as add-on therapy for difficult-to-control Type 2-high asthma. As allergy specialists manage a spectrum of diseases for which biologics may be appropriate, it is important to understand their prescribing patterns.
Source: Annals of Allergy, Asthma and Immunology - July 2, 2020 Category: Allergy & Immunology Authors: Merin Kuruvilla, Barbara Ariue, John J. Oppenheimer, Umesh Singh, Jonathan A. Bernstein Source Type: research
Gene Co-expression Network Analysis for Identifying Modules and Functionally Enriched Pathways in Vitiligo Disease: A Systems Biology Study.
Abstract
Vitiligo is the most common cause of skin, hair, and oral depigmentation which is known as an autoimmune disorder. Genetic and environmental factors have important roles in the progression of the disease. Dysregulation of gene expression, like microRNAs (miRNA), may serve as major relevant factors. Several biological processes are involved in vitiligo disease and developing a comprehensive approach helps us to better understand the molecular mechanisms of disease. In this research, we describe how a weighted gene co-expression network analysis as a systems biology approach assists to define the primary ge...
Source: Iranian Journal of Allergy, Asthma and Immunology - October 18, 2020 Category: Allergy & Immunology Authors: Derakhshani A, Mollaei H, Parsamanesh N, Fereidouni M, Miri-Moghaddam E, Nasseri S, Luo Y, Safarpour H, Baradaran B Tags: Iran J Allergy Asthma Immunol Source Type: research
Biologics and Novel Therapies for Food Allergy
Food allergy is a significant public health burden affecting around 10% of adults and 8% of children. Although the first peanut oral immunotherapy product received Food and Drug Administration approval in 2020, there is still an unmet need for more effective therapeutic options that minimize the risk of anaphylaxis, nutritional deficiencies, and patient ’s quality of life. Biologics are promising modalities, as they may improve compliance, target multiple food allergies, and treat other concomitant atopic diseases. Although omalizumab has been evaluated extensively, most biologics are more novel and have broader immunolo...
Source: Immunology and Allergy Clinics of North America - March 25, 2021 Category: Allergy & Immunology Authors: Sultan Albuhairi, Rima Rachid Source Type: research
P117 real-world perspectives of health care providers delivering the first approved treatment for peanut allergy
In January 2020, Peanut (Arachis hypogaea) Allergen Powder-dnfp (PTAH) became the first treatment for Peanut Allergy (PA) approved by the US Food and Drug Administration (FDA). The adoption of innovative new therapies requires consideration of the skills, logistics and practicalities required for implementation.
Source: Annals of Allergy, Asthma and Immunology - November 1, 2021 Category: Allergy & Immunology Authors: A. Anagnostou, C. Lawrence, P. Swinburn, S. Tilles, S. Laubach, S. Acaster, S. Donelson, M. Yassine, A. Nowak-Wegrzyn Source Type: research
